|Bid||0.00 x 20000|
|Ask||0.00 x 20000|
|Day's range||194.50 - 194.50|
|52-week range||152.30 - 205.95|
|Beta (5Y monthly)||0.16|
|PE ratio (TTM)||41.92|
|Forward dividend & yield||2.14 (1.09%)|
|Ex-dividend date||06 Sept 2022|
|1y target est||N/A|
Shares of uniQure (NASDAQ: QURE) climbed 14.61% on Wednesday. The stock jumped after the Food and Drug Administration (FDA), on Tuesday, approved Hemgenix (etranacogene dezaparvovec-drlb), a one-time gene therapy for hemophilia B. It was developed by uniQure, but CSL will commercialize the therapy. Hemophilia B, also known as Christmas disease, is rare.
uniQure (QURE) shares rise after its partner CSL Limited received FDA nod for one-time gene therapy, Hemgenix, for treating adults with Hemophilia B.
Shares of Arcturus Therapeutics Holdings (NASDAQ: ARCT) are skyrocketing today, up by 26.5% as of 11:15 a.m. ET. The huge gain came after Arcturus announced yesterday that it has entered into a strategic collaboration with CSL Seqirus, a unit of CSL Limited (OTC: CSLL.Y). The two companies plan to work together to develop and market messenger RNA (mRNA) vaccines targeting COVID-19, flu, pandemic preparedness, and three other respiratory infectious diseases.